Clinical Trial Update: Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients [Phase 2, Phase 3]

View source ↗

Summary

A neoadjuvant trial comparing serplulimab plus bevacizumab with FOLFOX versus FOLFOX alone in RAS/BRAF wild-type, pMMR/MSS colorectal cancer with liver metastas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)
• Serplulimab (serplulimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer, Liver Metastases | Phase 2, Phase 3 | Status: RECRUITING